Lilly’s monoclonal antibody, Taltz, which is already approved for psoriatic arthritis and plaque psoriasis has won its third approval. The FDA has cleared its use in active ankylosing spondylitis (AS), a chronic inflammatory rheumatic disorder that affects the pelvic joints and spine, and can be characterized by inflammatory back pain, stiffness and impaired function and … Continue reading Lilly’s Taltz wins third approval, this time in patients with active ankylosing spondylitis